Liposome-mediated delivery of oligodeoxynucleotides in vivo

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 9, Issue 3, 2002, Pages 169-180

  Dass, Crispin R ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

Antisense; Liposome; Oligodeoxynucleotide; Oligonucleotide; Transfection

Indexed keywords

LIPOSOME; OLIGODEOXYNUCLEOTIDE;

ARTICLE; BASE PAIRING; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENZYME ACTIVITY; GENE TARGETING; GENE TRANSFER; GENETIC TRANSFECTION; PRIORITY JOURNAL; PROMOTER REGION; RNA DEGRADATION; TRANSCRIPTION REGULATION;

EID: 0036638142     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/15227950290097606     Document Type: Article

References (110)

1. Factors affecting the specificity and mechanism of action of antisense oligonucleotide
2. Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the Human Papillomavirus Type 16 E6 gene
3. Cationic lipid-based delivery system for systemic cancer gene therapy
4. Evidence for three-dimensional interlayer correlations in cationic lipid-DNA complexes as observed by cryo-electron microscopy
5. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides
6. Mac-1 (CDI1b/CD18) is an oligodeoxynucleotide binding protein
7. Cationic prophyrins: Novel delivery vehicles for antisense oligodeoxynucleotides
8. Determination of cellular internalization of fluoresceinated oligonucleotides
9. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
10. Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy
11. Electroporation of synthetic oligodeoxyribonucleotides: A novel technique for ex vivo bone marrow purging
12. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PA-MAM dendrimers
13. Intravenous administration of stabilized antisense lipid particles (SALP) leads to activation and expansion of liver natural killer cells
14. Hypothesis: A naked plasmid DNA is taken up by cells in vivo by a receptor-mediated process
15. Naked DNA delivered intraportally expresses in hepatocytes
16. Target site selection for an RNA-cleaving catalytic DNA
17. Delivery and pathway in MCF7 cells of DNA vectorized by cationic liposomes derived from cholesterol
18. Rapid nuclear accumulation of injected oligodeoxyribonucleotides
19. Characterization of the nuclear-binding sites of oligodeoxyribonucleotides and their analogues
20. Optimal lipofection reagent varies with the molecular modifications of the DNA
21. The structure of DNA complexes with cationic liposomescylindrical or flat bilayers?
22. Lipoplexes and tumours
23. Delivery of lipoplexes for genotherapy of solid tumours: Role of vascular endothelial cells
24. Barriers to liposomal gene transfer into solid tumours
25. Liposomes containing cationic dimethyl dioctadecyl ammonium bromide (DDAB): Formulation, quality control and lipofection efficiency
26. A microsphere-lipoplex (microplex) vector for targeted gene therapy of cancer. I. Construction and in vitro evaluation
27. Novel cationic amphiphiles as delivery agent for antisense oligonucleotides
28. Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides
29. Plasmid DNA entry into postmitotic nuclei of primary rat myotubes
30. Translocation of RNA-coated gold particles through the nuclear pores of oocytes
31. The effects of variations in the number and sequence of targeting signals on nuclear uptake
32. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer
33. Movement of a karyophilic protein through the nuclear pores of oocytes
34. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations
35. Intracellular disposition and metabolism fluorescently labelled unmodified and modified oligonucleotides microinjected into mammalian cells
36. Water-soluble, meso-substituted cationic porphyrins - A family of compounds for cellular delivery of oligonucleotides
37. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes
38. Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker
39. Nucleocytoplasmic transport
40. Hydration of lipoplexes commonly used in gene delivery: Follow-up by laurdan fluorescence changes and quantification by differential scanning calorimetry
41. Cellular uptake and sub-cellular distribution of phosphorothioate oligonucleotides into cultured cells
42. RNA export
43. Phosphorothioate oligonucleotides reduce melanoma growth in a SCID-hu mouse model by a nonantisense mechanism
44. Intratumoral injection of oligonucleotides to the NF-κB binding site inhibits cachexia in a mouse tumor model
45. Intravenous injection of oligodeoxynucleotides to the NF-κB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice
46. Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible
47. Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes
48. Effect of polyisobutylcyanoacrylate nanoparticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells
49. Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV E7 mRNA in CaSki cells
50. Liposomes and lipidic particles in gene therapy
51. A protein that shuttles between the nucleus and the cytoplasm is an important mediator of RNA export
52. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line
53. Intracellular distribution of microinjected antisense oligonucleotides
54. Fate of cationic liposomes and their complex with oligonucleotide in vivo
55. Systemic gene delivery expands the repertoire of effective antiangiogenic agents
56. Characterization of oligonucleotide transport into living cells
57. Synthetic DNA delivery systems
58. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus
59. Mechanisms of nuclear protein import
60. Endocytosis and molecular sorting
61. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus
62. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle cell proliferation in vivo
63. In vivo transfection of cis element "decoy" against nuclear factor-κB binding site prevents myocardial infarction
64. Cationic lipid-mediated transfection of cells in culture requires mitotic activity
65. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles
66. RNA transport
67. Cationic lipid is not required for selective inhibitory activity of ICAM-1 phosphorothioate antisense oligonucleotides in keratinocytes
68. Characteristics of oligonucleotide uptake in human keratinocyte cultures
69. Formivirsen
70. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide
71. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm
72. Nuclear import of polypeptides, polynucleotides and supramolecular complexes
73. Structure of DNAcationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packaging regimes
74. Electroporation-mediated delivery of 3′-protected phosphodiester oligodeoxynucleotides to the skin
75. Cell-surface pertubations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides
76. Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: Physicochemical and transfection studies
77. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cell proliferation
78. New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury
79. Lipid-based formulations of antisense oligonucleotides for systemic delivery applications
80. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: Formation of novel small multilamellar vesicle structures
81. Modified deoxyoligonucleotides stable to exonuclease degradation in serum
82. Cationic liposome and plasmid DNA complexes formed in the serum-free medium under optimum transfection condition are negatively charged
83. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O
84. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells
85. The nuclear pore complex: From molecular architecture to functional dynamics
86. Suppression of smooth muscle cell (SMC) proliferation by a c-myc RNA-cleaving deoxyribozyme
87. Catalytic nucleic acids: From lab to applications
88. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide
89. Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme)
90. Suppressed severity of collagen-induced arthritis by in vivo transfection of NF-κB decoy oligodeoxynucleotides as gene therapy
91. Transcription factor decoy study to study the molecular mechanism of negative regulation of renin gene expression in the liver in vivo
92. Antisense gene inhibition by oligonucleotides containing C-5 propene pyrimidines
93. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): Effects on the pharmacokinetics of liposomal vincristine
94. Live confocal microscopy of oligonucleotide uptake by keratinocytes in human skin grafts on nude mice
95. Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle
96. Cationic lipid binding to DNA: Characterization of complex formation
97. Fusion of cationic liposomes with mammalian cells occurs after endocytosis
98. Antisense c-myc oligodeoxyri-bonucleotide cellular uptake
99. In vivo gene therapy with a cationic polymer markedly enhances the antitumor activity of antiangiogenic genes
100. Mechanisms of oligonucleotide uptake by cells: Involvement of specific receptors?
101. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells
102. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes
103. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids
104. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells
105. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA
106. Expression of naked plasmid DNA injected into the afferent and efferent vessles of rodent and dog livers
107. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides
108. Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery